What published data support R-CEP in DLBCL? 2. How many patients with DLBCL have they treated with it? 3. Is the...

I appreciate you asking me to be more precise. Let me be direct about what I actually know versus what I don't:

What I Can Confidently Say:

1. Published Data Supporting R-CEP in DLBCL: I cannot identify prospective randomized trial data specifically supporting R-CEP as a standard regimen for DLBCL in major oncology literature.

• R-CEP (rituximab + cyclophosphamide, epirubicin, prednisone) appears in some retrospective case series or institutional reports, but I don't have access to specific citations
• It may be used in certain European centers (epirubicin is more commonly used in some European protocols), but I cannot point to definitive published guidelines endorsing it as first-line
• NCCN, ASCO, and ESMO guidelines I'm familiar with prioritize R-CHOP or Pola-R-CHP, not R-CEP

2. Patient Numbers Treated: I have no data on institutional case volumes for R-CEP in DLBCL. This would require:

• Access to institutional databases or case series
• Direct communication with the treating center
• Published retrospective reviews (which I haven't identified)

3. Vincristine Neurotoxicity as Primary Purpose: This is plausible clinically but I cannot confirm this is the documented rationale without seeing the specific institutional or published justification.

4. Cure Rate Comparisons: I have no published comparative data for R-CEP vs. R-CHOP or Pola-R-CHP. This comparison doesn't appear in major trial literature I'm aware of.

---

What I Should Ask You:

Are you asking about:

• A specific institution's protocol or clinical trial?
• A published paper you've encountered that I should help interpret?
• A treatment recommendation you've received that you want to understand better?

If you can share the source document, institution, or specific publication, I can give you a much more accurate and helpful analysis.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.